IR-Med Statistics
Total Valuation
IR-Med has a market cap or net worth of $45.95 million. The enterprise value is $45.87 million.
| Market Cap | 45.95M |
| Enterprise Value | 45.87M |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
IR-Med has 70.70 million shares outstanding. The number of shares has increased by 1.60% in one year.
| Shares Outstanding | 70.70M |
| Shares Change (YoY) | +1.60% |
| Shares Change (QoQ) | +0.05% |
| Owned by Insiders (%) | 67.81% |
| Owned by Institutions (%) | n/a |
| Float | 22.53M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1,351.60 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1,349.01 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.92
| Current Ratio | 0.92 |
| Quick Ratio | 0.92 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -221.95 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -728.15% |
| Return on Capital (ROIC) | -1,802.14% |
| Revenue Per Employee | $3,778 |
| Profits Per Employee | -$468,444 |
| Employee Count | 9 |
| Asset Turnover | 0.03 |
| Inventory Turnover | -1,384,322,482,068,543.00 |
Taxes
In the past 12 months, IR-Med has paid $2,000 in taxes.
| Income Tax | 2,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -41.96% in the last 52 weeks. The beta is 1.26, so IR-Med's price volatility has been higher than the market average.
| Beta (5Y) | 1.26 |
| 52-Week Price Change | -41.96% |
| 50-Day Moving Average | 0.70 |
| 200-Day Moving Average | 1.06 |
| Relative Strength Index (RSI) | 55.38 |
| Average Volume (20 Days) | 187 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, IR-Med had revenue of $34,000 and -$4.22 million in losses. Loss per share was -$0.06.
| Revenue | 34,000 |
| Gross Profit | -5,000 |
| Operating Income | -4.22M |
| Pretax Income | -4.22M |
| Net Income | -4.22M |
| EBITDA | -4.20M |
| EBIT | -4.22M |
| Loss Per Share | -$0.06 |
Balance Sheet
The company has $408,000 in cash and $320,000 in debt, giving a net cash position of $88,000 or $0.00 per share.
| Cash & Cash Equivalents | 408,000 |
| Total Debt | 320,000 |
| Net Cash | 88,000 |
| Net Cash Per Share | $0.00 |
| Equity (Book Value) | -86,000 |
| Book Value Per Share | -0.00 |
| Working Capital | -42,000 |
Cash Flow
In the last 12 months, operating cash flow was -$2.69 million and capital expenditures -$2,000, giving a free cash flow of -$2.69 million.
| Operating Cash Flow | -2.69M |
| Capital Expenditures | -2,000 |
| Free Cash Flow | -2.69M |
| FCF Per Share | -$0.04 |
Margins
Gross margin is -14.71%, with operating and profit margins of -12,402.94% and -12,400.00%.
| Gross Margin | -14.71% |
| Operating Margin | -12,402.94% |
| Pretax Margin | -12,400.00% |
| Profit Margin | -12,400.00% |
| EBITDA Margin | -12,338.24% |
| EBIT Margin | -12,402.94% |
| FCF Margin | -7,917.65% |
Dividends & Yields
IR-Med does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.60% |
| Shareholder Yield | -1.60% |
| Earnings Yield | -9.17% |
| FCF Yield | -5.86% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on February 26, 2020. It was a reverse split with a ratio of 1:1000.
| Last Split Date | Feb 26, 2020 |
| Split Type | Reverse |
| Split Ratio | 1:1000 |
Scores
IR-Med has an Altman Z-Score of -20.07 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -20.07 |
| Piotroski F-Score | 2 |